Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which current pharmacological treatment remains largely symptomatic, with cholinesterase (ChE) inhibitors continuing to represent an important therapeutic strategy. Diketopyrrolopyrroles (DPPs) are a class of planar N -containing heterocycles widely explored as high-performance dyes, pigments and photoactive materials. However, their potential for direct enzyme inhibition remains largely unexplored. In this work, a series of eleven structurally diverse DPP derivatives was evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) to investigate the potential of this scaffold to support ChE inhibition and provide preliminary structure-activity relationships (SAR). The results demonstrated that several cationic derivatives displayed strong inhibitory activities, with derivative 14 emerging as the most active derivative against both AChE (IC 50 0.13 ± 0.03 µM) and BuChE (IC 50 0.21 ± 0.02 µM). Preliminary SAR analysis suggested important roles for pyridinium-containing groups and spacer architecture in modulating cholinesterase inhibition. Molecular docking studies provided plausible structural hypotheses for the interaction of the most active compounds within the ChEs binding site, including predicted engagement to both the catalytic active site (CAS) and peripheral anionic site (PAS). However, physicochemical and ADMET predictions raised some concerns regarding molecular size, permanent cationic character, permeability and predicted brain exposure. Overall, these findings identify functionalized DPPs as an enzyme-active worthy of further exploration and provide a chemically flexible starting point for the development of second-generation ChE inhibitors with improved properties.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: